A 53-year-old Caucasian man with a body mass index of 32 was referred to our metabolic clinic by his general practitioner with a 14-year history of chronic sleep disturbance and fatigue. The patient complained of being unable to sleep before 03.00-04.00 and found it extremely difficult to wake up for work at about 08.00. If left undisturbed, usual waking times were around 12.00-13.00. The patient also described occasional days where he would have a 24-48-hour period without sleep, followed by prolonged sleep usually lasting about 15 hours. Prior to presentation he had consulted many physicians and tried hypnotic medication with no effect. Apart from an episode of bacterial epiglottitis in 1994, there was no other significant medical history and his clinical examination was unremarkable.
Basic laboratory investigations, including full blood count, liver function tests and urea and electrolytes, were all within normal limits. A morning (09.00) pituitary profile revealed an abnormally low cortisol (86 nmol/l) with luteinising hormone, follicle-stimulating hormone, prolactin, thyroid-stimulating hormone and free T4 all within normal range. A normal response to a short synacthen test excluded hypoadrenalism. The patient's magnetic resonance imaging brain scan was normal, and sleep oximetry revealed no significant hypoxia. At this point, delayed sleep phase syndrome (DSPS) was clinically suspected (Table 1) . Timed urinary 6-sulphatoxymelatonin (aMT6), a melatonin metabolite that correlates well with serum melatonin secretion, was measured over two days in urinary aliquots by radioimmunoassay. An abnormal melatonin secretion pattern was noted, with urinary aMT6 only starting to rise at about 03.00 on both days (Figure 1 ), whereas it was expected to have risen about six hours previously.
The diagnosis of DSPS was confirmed and the patient was started on 3 mg of oral melatonin at 20.00. His sleeping pattern returned to normal with sleep onset between 22.30-23.30 and waking around 08.00. Repeat measurement of his urinary aMT6 excretion revealed a normal physiological pattern (Figure 2 
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Sleep-related complaints are common, with insomnia and associated daytime dysfunction reported in 10-34% of patients attending primary care. 1 Circadian rhythm sleep disorders (CRSDs) are characterised by a lack of synchronisation between a person's biological clock and the environmental 24-hour schedule. 2 The central circadian pacemaker or 'master' biological clock consists of a specialised group of neurons in the suprachiasmatic nucleus of the hypothalamus. This central pacemaker regulates circadian rhythms such as the sleep-wake cycle, body temperature and the secretion of hormones, including melatonin, from the pineal gland. 3 Few large-scale studies on patients with CRSDs have been performed and data on prevalence remain scarce. 2 Six categories of CRSDs have been described (Table 1) and studies indicate that the majority of these patients were suffering from DSPS. 2, 4 In DSPS, sleep-onset and wake times are intractably delayed, with extreme difficulty in waking at the desired time in the morning. There is a relative inability to advance the sleep phase to earlier hours. 4 Sporadic non-circadian days may also occur (with no sleep for an entire day, night and even part of the next day), followed by a prolonged period of sleep lasting 12-18 hours. 4 In addition to the abnormal timing of the sleep-wake cycle in DSPS, other circadian rhythms such as core body temperature and the hormonal secretion of melatonin and cortisol have also been reported to be delayed. 5, 6 The circadian secretion of melatonin normally rises at about 21.00, peaks at 03.00 and is barely detectable at 09.00. 7 The disorder is best diagnosed by clinical interview and a week of actigraphy (gross motor activity monitoring) or sleep diary. Melatonin secretion pattern and core body temperature measurement over 36 hours are additional diagnostic tools. 2 Polysomnography has been described as inadequate in the assessment of CRSDs. 2 The exact cause of DSPS remains unclear. Various genetic factors such as the HLA DR1 serotype and structural polymorphisms in the human period 3 (hPer3) gene have been associated with DSPS. 8, 9 The aim of treatment in DSPS is to advance the onset of the sleep phase. Recognised means of achieving this include chronotherapy (a behavioural technique), brightlight therapy and daily timed melatonin administration. 2, 10 Melatonin has been described as a 'chronobiotic', referring to its capability to synchronise circadian rhythm. The ability of exogenous melatonin to phaseadvance the circadian clock, as seen in our patient, may be attributed to its action on melatonin receptors (MT2) in the suprachiasmatic nucleus.
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Endogenous pineal melatonin secretion is normally under the control of the suprachiasmatic nucleus, which receives input about the environmental light/dark cycle via the retinohypothalamic tract. Thus by measuring the pattern of melatonin secretion it is possible to obtain a picture of the 'timing' of the central pacemaker, 3 which in our patient ( Figure 1 ) was markedly abnormal. Melatonin is involved in the mediation of sleep, most likely by inhibiting the circadian wakefulness generating mechanism. Although there is strong evidence to suggest that melatonin plays an important role in the pathophysiology of CRSDs, additional large-scale studies are needed to elucidate whether abnormal melatonin secretion is a causal factor in these disorders. 12 Melatonin is also being extensively investigated for its diverse antioxidant, oncostatic and immunomodulatory properties. 
